Zhitong Finance App News. Recently, Tiger Pharmaceuticals (03347) released the “2023 Sustainability and Environmental, Social and Corporate Governance Report”. This report is the sixth sustainability report issued by Tiger Pharmaceuticals, which discloses the company's actions and progress in the fields of corporate governance, environment and society to key stakeholders.

Through an integrated R&D service platform covering the entire industry chain, Tiger Pharmaceuticals provides one-stop services for drug and medical device development, spanning the entire drug development process and device development life cycle, including laboratory services, analysis and testing, registration and reporting, clinical development and operation, post-marketing and real-world research. By the end of the reporting period, Tiger Pharmaceuticals had participated in and contributed to the research and development of 99 Class I innovative drugs already marketed in China.

According to the ESG report, Tiger Pharmaceuticals has established a complete ESG management system. The board of directors fulfills supervisory responsibility for the company's ESG matters, and the compliance and ESG committee is chaired by the general manager, which aims to establish a long-term sustainable ESG management structure. At the same time, by establishing a normalized communication mechanism with stakeholders, the company thoroughly understands their opinions, needs, and expectations of the company, and actively responds to stakeholders' concerns by maintaining two-way communication as a basis for fulfilling its responsibility for sustainable development. In 2023, Tiger Pharmaceuticals' MSCI ESG rating was upgraded to AA, and the CDP climate change questionnaire response received a B rating.

Tiger Pharmaceuticals mainly carries out clinical operations and project management, providing integrated services from technical support to marketing consulting and post-marketing clinical research services. It does not involve drug development and production, and the overall environmental management risk is low.

Among them, greenhouse gas emissions from the operation process mainly come from range 2 (indirect) greenhouse gas emissions during the daily office process, the consumption of outsourced electricity and outsourced heat, and range 1 (direct) greenhouse gas emissions from the gasoline and diesel consumption process of own vehicles. During the reporting period, the company's per capita greenhouse gas emissions were 0.27 tonnes of carbon dioxide equivalent per person (excluding Fangda Holdings), a decrease of 64.00% compared to the base year 2019.

In 2023, the total amount of hazardous waste generated by the company was 268.21 tons, and the per capita water consumption was 5.74 m3/person, a decrease of 88.13% compared to 2019. The per capita comprehensive energy consumption was 0.51 MWh/person, a decrease of 62.22% compared to 2019.

At the social level, Tiger Pharmaceuticals is committed to creating a diverse, equal, open, inclusive, collaborative and mutual assistance working environment, so that every employee can feel their own value and sense of belonging. It is worth mentioning that the company provides statutory and additional vacations and benefits to all female employees, and invites external experts and physicians to give lectures on women's health to answer questions about the popularization of gynecological health knowledge. In 2023, Tiger Pharmaceuticals had a total of 9,020 employees, including 8,850 full time and 170 part-time workers, of which women accounted for 82.56% of the full-time employees.

Tiger Pharmaceuticals provides all employees with complete internal training programs and unobstructed development channels. Relying on the newly developed Tiger online learning platform system, it gradually integrates various resources such as the talent system, curriculum system, lecturer team, training management system, etc., to improve the efficiency of training management and the quality of systematic training construction. At the same time, the company has accumulated rich professional experience in past employee training, incubated a series of high-quality courses, and currently has special leadership course training covering managers at all levels.

In addition, through a strategic cooperative talent training model, the company signed strategic cooperation agreements with universities to carry out targeted training in the form of school-enterprise cooperation. Relying on resources such as job internships, professional teaching, and skill training, the company jointly trains clinical pharmacy professionals. While enriching Tiger Pharmaceuticals's reserve talent pool, it also contributes more outstanding new forces to the clinical industry. During the reporting period, the company invested 6.3441 million yuan in employee training. The employee training coverage rate reached 100%, and the training time per employee was 109.68 hours.

At the level of supply chain management, Tiger Pharmaceuticals has established a complete supplier management system to strengthen supply chain management capabilities. The group implements internal management mechanisms in accordance with standardized supplier management systems; grasps key management boundaries through hierarchical supplier management; carries out regular supplier inspection actions to identify and investigate potential risks; focuses on improving internal supply chain management capabilities and establishes a complete procurement training and assessment system.

Among them, Tiger Pharmaceuticals conducts social responsibility due diligence investigations on clinical material suppliers to understand the supplier's ESG management status and ensure the true effectiveness of supplier data. During the reporting period, the company carried out due diligence work on major clinical material suppliers (accounting for more than 75% of the procurement amount), and all suppliers passed the questionnaire review.

In terms of innovative services, Tiger Pharmaceuticals uses independent R&D, cooperative research, and advanced industry tools to fully promote the digital upgrading of the entire clinical research process, and build an ecological, intelligent and integrated CRO service platform centered on patients. At the same time, through industry-university-research cooperation with universities, the company actively promotes R&D transformation of innovative drugs and medical devices, empowering the biomedical industry throughout the life cycle from innovation to product.

In the future, Tiger Pharmaceuticals will continue to adhere to the concept of “service innovation to build health together”, continuously optimize ESG management systems and capabilities, effectively deepen scientific and technological innovation development capabilities, and contribute to the sustainable development of the global healthcare industry with higher quality services and a stronger sense of social responsibility.

(Link ESG researcher Deng Shixia)